TauRx Therapeutics Ltd (company statement), 2024-07-01: Company statement announcing submission of a UK Marketing Authorisation Application to the MHRA for hydromethylthionine mesylate in Alzheimer's disease, citing LUCIDITY and the two earlier phase 3 trials, and noting MHRA Innovative Licensing and Access Pathway designation.
The MAA is based on the totality of evidence available from the recently released 24-month Phase 3 LUCIDITY data and two earlier Phase 3 trials in mild to moderate AD.
web page
TauRx Therapeutics Ltd (company statement), 2024-07-01: Company statement announcing submission of a UK Marketing Authorisation Application to the MHRA for hydromethylthionine mesylate in Alzheimer's disease, citing LUCIDITY and the two earlier phase 3 trials, and noting MHRA Innovative Licensing and Access Pathway designation. Company statement (attributed to TauRx, not an independent source). Date of submission 2024-07-01 per the parallel BusinessWire release. Funding: TauRx is the applicant and funder of all cited trials. Conflicts: the statement is by the sponsor. Records the existence of a regulatory submission; it does not record a regulatory decision. Study type: other.
